Cure Ventures
Venture capitalActively deployingBoston · Pre-Seed–Series A · 22 people tracked
Also known as CURE VENTURES MANAGEMENT, LP
Investment thesis
Cure Ventures backs entrepreneurs developing breakthrough therapeutics to treat life-altering diseases. The firm emphasizes that people, not just capital, drive the creation of life-changing medicines, and it works hands-on alongside founders from company formation through to successful outcomes. Drawing on a legacy of notable labs, discoveries, and companies, Cure aims to impart lessons learned and support new drug-discovery modalities. Its culture centers on respect and a rigorous, fact-based commitment to science, with the ultimate goal of bringing patients closer to cures.
Source: firm website, verified Aug 25, 2026.
Team · 22 people
from the firm's website & public directories
Founder mafia
3 people who came through Cure Ventures went on to found or lead other companies.
What they invest in
from 15 of 27 portfolio companiesBiotech ×14Healthtech ×10Medical Devices ×2Deep Tech ×1Digital Health ×1Longevity ×1SaaS ×1
HQs:United States×9
Investments · 27 tracked
founders shown can be your intro pathBy year:2025 · 32024 · 12022 · 15 dated
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Chief Scientific Advisor and Director)Cam Gallagher(Executive Officer, Director)inJohn Maroney(Executive Officer, Director)
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)in
Board seatAnnie Mitsak· per SEC Form D
Co-investorsMission Bay CapitalMission Biocapital
BiotechBoston, US
Ronald D. Seidel, III(Executive Officer, Director)
BoardCameron Gallagher(Director)Rodolfo Chaparro(Director)Andrew King(Executive Officer)in
Board seatLou Tartaglia· per SEC Form D
BiotechCambridge, US
Peter Fuhrken(Director)Howard Federoff(Executive Officer, Director)Nick Manusos(Executive Officer, Director)Martin Ostrowski(Executive Officer)Jonathan Yeh(Director)
BoardJeff Goater(Director)in
Board seatDavid Fallace· per SEC Form D · $81.8M raise · filed Mar 2024
Co-investorsThe Column Group
Unlocking post-translational protein modification using chemical biology and computational approaches to develop drugs for previously undruggable oncology targets.
BiotechCambridge, US
Praveen Tipirneni(Director)Xu Wu(Director)
BoardSeth Lieblich(Director)inMichael Aberman(Director)Drew King(Executive Officer)
Board seatDavid Fallace· per SEC Form D
Discovering and developing therapeutic molecules derived from exercise to treat neurodegenerative diseases including Parkinson's.
Aevum develops therapeutic molecules derived from exercise to treat disease.
BiotechLongevity
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.
BiotechHealthtechCambridge, US
Co-investorsCatalio Capital Management, LPVivo CapitalCatalio Capital ManagementNovo HoldingsThird Rock Ventures
Engineering cancer medicines that conditionally assemble in the tumor microenvironment across multiple therapeutic modalities.
Advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying treatment for neurological disorders like Parkinson's disease.
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions such as Parkinson's disease.
BiotechHealthtechMedical Devices
Co-investorsThe Column Group
Developing precision biologics to treat autoimmune and inflammatory diseases with exceptional safety profile.
Kobuk Therapeutics is developing a biologics platform aimed at treating autoimmune diseases by resetting the immune system to a healthy state while preserving protective immunity.
BiotechHealthtech
Permeasis Therapeutics is developing a Membrane Translocation Domain (MTD) platform that enables intracellular delivery of proteins and other large therapeutic macromolecules to the cytosol and intracellular compartments.
BiotechDeep TechBoston, US
Providing a virtual-first care delivery platform with integrated primary care, behavioral health, urgent care, and supplemental benefits.
Recuro is a virtual-first digital health platform that provides primary care, behavioral health, urgent care, and supplemental benefits (pharmacy, care management, advocacy) to patients, employers, health plans, and providers.
Digital HealthHealthtechSaaSRichardson, US
Michael Brombach(Chief Executive Officer and Co-Founder)Michael Gorton(Chief Executive Officer)inDr. Kate Sowerwine(Chief Medical Officer)John Halsey(Director)Kris Engskov(Director)William Paiva(Director)
Co-investors1843 Capital4D CapitalARCH Venture PartnersCortado VenturesGlobal Insurance Accelerator
Tasca develops new cancer medicines using a drug discovery platform that identifies and maps novel lipid-binding pockets on proteins.
BiotechHealthtech
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsAN Venture PartnersThe Column Group
Developing therapeutics for neurological diseases with high unmet need using translational approaches.
US-based neuroscience company and AN Venture Partners portfolio investment.
Co-investorsAN Venture Partners
Triton Therapeutics is a clinical-stage biotechnology company developing first-in-class medicines for autoimmune and fibrotic diseases.
BiotechHealthtechStamford, US
Timothy Shannon(Director)Elena Grigoryeva(Director)
BoardAnnie Mitsak(Director)Paul Fonteyne(Executive Officer, Director)
Co-investorsCanaan Partners
Developing a novel antibody-enzyme fusion to target tumors and trigger immune response through fusion protein technology.
XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses.
BiotechHealthtechCambridge, US
Crosslink develops a modular biologic domain that assembles therapeutics within tumors to improve tumor-specific targeting and activity.
BiotechHealthtech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companiesClasp Therapeutics · catalyticagency.com · Jun 18, 2026
Tasca Therapeutics · nasdaqprivatemarket.com · Apr 3, 2026
Alessa Therapeutics · alessatherapeutics.com · Oct 21, 2025
Crosslink Therapeutics · xlinktx.com · May 10, 2025
Frequently asked questions
- How many investments has Cure Ventures made?
- Cure Ventures has 26 tracked investments, including 3 dated in the last 24 months.
- What stage does Cure Ventures invest at?
- Cure Ventures invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Cure Ventures focus on?
- Cure Ventures focuses on Biotech.
- Where is Cure Ventures located?
- Cure Ventures is headquartered in Boston, US.
- Who does Cure Ventures co-invest with?
- Cure Ventures most often shares deals with AN Venture Partners, The Column Group, 8VC, among 13 tracked co-investors.
Images
Co-investors · 2
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Firms observed investing alongside Cure Ventures, from public investor directories. Shared companies are the overlap with Cure Ventures's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Felicis Ventures is a venture capital firm that backs founders primarily at the Seed and Series A stages, frequently leading or co-leading rounds. It operates with a founder-first approach, including a founder pledge and voting commitments.
Fly Ventures is an early-stage venture firm that backs founders at the zero-to-one stage, with portfolio companies going on to raise substantial follow-on funding from top US and European VCs.
Hoxton Ventures is an early-stage venture capital firm that backs pre-seed and seed companies, often investing before revenue or product and offering hands-on support to founders.